Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1994-03-22
1995-07-25
Tsang, Cecilia
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
549354, 4352541, A61K 31335, C07D31300
Patent
active
054362636
ABSTRACT:
The present invention is directed to compounds which inhibit farnesyl-protein transferase (FPTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras.
REFERENCES:
patent: 5043268 (1991-08-01), Stock
patent: 5141851 (1992-08-01), Brown et al.
patent: 5245061 (1993-09-01), Singh
patent: 5256399 (1993-10-01), Sessler
patent: 5260465 (1993-11-01), Singh et al.
patent: 5260479 (1993-11-01), Singh
patent: 5276217 (1994-01-01), Tius
patent: 5326773 (1994-07-01), De Solms
patent: 5340828 (1994-08-01), Graham
patent: 5352705 (1994-10-01), Deana
Kohl, N. E. et al., "Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice", Proc. Natl. Acad. Sci., USA, vol. 91, pp. 9141-9145, (1994).
Bos, J. L., ras Oncogenes in Human Cancer: A Review, (1989), Cancer Research, 49, pp. 4682-4689.
Gibbs, J. B., Ras C-Terminal Processing Enzymes-New Drug Targets?, (1991), Cell, 65, 1-4.
Gibbs, J. B. et al., Selective Inhibition of Farnesyl-Protein Transferase Blocks Ras Processing in Vivo, (1993), The Journal of Biol. Chemistry, 268, No. 11, pp. 7617-7620.
Goldstein, J. S., et al., Journal of Biological Chemistry, vol. 266, No. 24, pp. 15575-15578 (1991).
James, G. L. et al., Benzodiazepine Peptidomimetics: Potent Inhibitors of Ras Farnesylation in Animal Cells, (1993), Science, 260, pp. 1937-1942.
Kohl, N. E. et al., Selective Inhibition of ras-Dependent Transformation by a Farnesyltransferase Inhibitor, (1993), Science, 260, pp. 1934-1937.
Leftheris, K. et al., Peptide Based P21RAS Farnesyl Transferase Inhibitors: Systematic Modification of the Tetrapeptide CA1A2X Motif, (1994), Bioorganic & Medicinal Chemistry Letters, 4, No. 7, pp. 887-892.
Pompliano, D. L. et al., Steady-State Kinetic Mechanism of Ras Farnesyl: Protein Transferase, (1992), Biochemistry, 31, pp. 3800-3807.
Qian, Y. et al., Design and Structural Requirements of Potent Peptidomimetic Inhibitors of p21ras Farnesyltransferase, (1994), The Journal of Biological Chemistry, 269, No. 17, pp. 12410-12413.
Reiss, Y. et al., Inhibition of Purified p21ras Farnesyl: Protein Transferase by Cys-AAX Tetrapeptides, (1990), Cell, 62, pp. 81-88.
Reiss, Y. et al., Sequence requirement for peptide recognition by rat brain p21 ras protein farnesyltransferase, (1991), Proc. Natl. Acad. Sci. USA, 88, pp. 732-736.
Schaber, M. D. et al., Polyisoprenylation of Ras in Vitro by a Farnesyl-Protein Transferase, (1990), The Journal of Biological Chemistry, 265, No. 25, pp. 14701-14704.
Katz Barry A.
Lingham Russell B.
Martin Isabel
Silverman Keith C.
Singh Sheo B.
Daniel Mark R.
DiPrima Joseph F.
Merck & Co. , Inc.
Muthard David A.
Tsang Cecilia
LandOfFree
Inhibitors of farnesyl-protein transferase does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibitors of farnesyl-protein transferase, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of farnesyl-protein transferase will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-739884